Recent Posts

AstraZeneca ponders $240b Gilead gamble

There are good reasons for Britain’s AstraZeneca Plc to consider what would be the biggest pharmaceuticals deal in history by combining with US peer Gilead Sciences Inc. They may not be good enough to offset the risks that go with mashing together drugmakers with a total market value of nearly $240 billion. AstraZeneca approached Gilead last month, Bloomberg News reported, ...

Read More »

Hydroxychloroquine farce has consequences

Follow the science— these are reassuring words in a pandemic like Covid-19, when widespread fear of a deadly virus can be exploited by unscrupulous politicians, snake-oil salesmen and cranks. Public trust in scientists has risen recently. But we may be hitting the limits of this trust, just as many countries enter the crucial phase of reopening their economies with a ...

Read More »

Airbus’s global footprint now a burden as sector shrinks

Bloomberg Over the past dozen years, Airbus SE has grown from a European planemaker with purely local production into a global manufacturer with assembly lines on three continents that give it more clout to win orders around the world. But as the aviation industry enters its most dramatic downturn ever, the company is finding that broad reach turning from an ...

Read More »
Send this to a friend